HELIOCARE 360° is a comprehensive photoprotection range designed to support dermatologists in the prevention and management of photo-induced skin damage.

Providing very high-level, full-spectrum daily protection against UVA (PA++++), UVB (SPF50>), visible light and infrared-A, HELIOCARE 360° uses its unique Fernblock® & ASPA-Fernblock® antioxidant technologies to clinically protect beyond typical sunscreen by defending the skin from within and helping repair daylight-induced damage.

Why Choose HELIOCARE 360°?

  • Very high-level, broad-spectrum UV protection

    UVB (SPF50>) and UVA (PA++++).

  • Fernblock®+ Antioxidant Technology

    Proven by dermatologists to help enhance protection from UVA, Visible Light, IR-A and free radical and repair DNA damage.

  • A sunscreen for everyone, for every day

    With unique formulas tailored for different skin types and special skin care concerns, finish and coverage preferences.

  • Holistic skin protection, inside and out

    With topical sunscreens and oral skin supplements.
Get Started

Personalised Daily Photoprotection for Every Patient Profile

HELIOCARE 360° is designed for everyday use across a wide range of patient needs, with advanced formulations tailored by skin type, indication, and finish preference. Each product provides dermatologist-aligned, full-spectrum protection against UVA, UVB, visible light and infrared-A, while also delivering targeted skincare benefits to support common dermatological concerns - such as acne-prone skin, pigmentation management, redness-prone skin, barrier support, hydration, and photoageing prevention.

  • Universal & Special Care Sunscreens

    Very high-level protection for all skin types & concerns.

  • Tinted Sunscreens

    Very high-level protection with skin-perfecting coverage.

  • Oral Skin Supplements

    Support topical protection and promote skin health from within.

  • Pediatrics Sunscreens

    Designed for babies and children from 6 months old

  • Body Sunscreens

    Very high-level sun protection and even coverage for the whole body
Get Started

Fernblock® & Dermatological Pathologies

Every HELIOCARE sunscreen and oral supplement product contains the unique Fernblock® Technology, a patented extract derived from the fern Polypodium leucotomos, exclusive to Cantabria Labs.

More than 50 clinical and scientific studies have demonstrated Fernblock® as a potent, bioactive antioxidant technology that, when used in HELIOCARE sunscreens and oral supplements, helps protect the skin from damage caused by exposure to UVB, UVA, Visible Light and Infrared-A.

Get Started

The Scientific and Clinical Literature Extensively Documents Fernblock’s Mechanism of Action

  • Protect the skin against damage caused by daylight: UVA, UVB, visible light and infrared-A1,2,3

  • Prevent collagen breakdown2

  • Protect and repairs skin cell DNA4

  • Prevent light-induced pigmentation5

  • Protect the skin’s immune system5

  • Improve the efficacy of SPF filters6

Oral Fernblock® & Supporting High-Risk Patients

HELIOCARE's oral supplement range provides photoprotection support using patented Fernblock® (Polypodium leucotomos) extract, developed as an adjuvant to topical sunscreen in patients where photoprotection is clinically critical. The clinical literature supports oral Fernblock® as an adjuvant in dermatological pathways linked to UV and visible light exposure, including:

Polymorphic light eruption (PMLE)

In placebo-controlled studies of around 80 PMLE patients, daily oral Fernblock® during sun exposure significantly reduced skin reactions and symptoms; 74% of those continuing use through summer reported minimal or no recurrence.7,8

Vitiligo

Placebo-controlled studies show improved re-pigmentation and higher response rates when oral Fernblock® is combined with NB-UVB phototherapy versus phototherapy alone, with effects also linked to reduced CD3/CD25 T-cell activity in PUVA regimens.9

Melasma & hyperpigmentation

Oral Fernblock® as an adjunct to hydroquinone and sunscreen produced significantly greater and faster mMASI score improvements than placebo, with 31% of patients achieving ≥75% improvement versus 6% on placebo alone.10

Photoageing & environmental oxidative stress

Studies show Fernblock® reduces UV- and pollution-induced ROS, MMP-1 collagen breakdown, and mitochondrial damage, while protecting Langerhans cells and fibroblasts against visible light and infrared-A exposure in vitro and in vivo.11

Actinic keratosis (AK)

Studies show oral and topical Fernblock® as an adjunct to PDT and cryotherapy improves AK clearance and AKASI scores versus standard care alone, with reviews reporting reduced CPDs, p53 activation, and lower recurrence risk.12

Oral Fernblock should be positioned as an adjunct to topical photoprotection, particularly for patients with pigment relapse risk, photosensitivity concerns, or those undergoing treatment plans where consistent sun protection is clinically important.

Request More Information

Introducing NEW ASPA-Fernblock® Technology

ASPA-Fernblock® is the latest evolution in skin photoprotection - a next-generation patented bioactive complex designed to enhance the protective benefits of HELIOCARE while supporting skin health beyond UV protection.

This innovative technology combines two powerful plant-based actives: Fernblock®+, Cantabria Labs' patented Polypodium leucotomos extract with clinically proven antioxidant and photoprotective properties, and ASPA, a patented extract derived from Aspalathus linearis (Rooibos), a plant naturally rich in flavonoids with recognised biological activity. Together, they create ASPA-Fernblock®, an additive complex exclusive to Cantabria Labs products.

ASPA-Fernblock® has been shown to enhance the efficacy of UV filters, supporting more comprehensive protection across the full spectrum of solar radiation, including UVA, UVB, visible light and infrared-A. It also delivers the OptiD Effect, helping to preserve vitamin D receptors under oxidative stress and supporting the skin's ability to utilise vitamin D more effectivtly.

Partner With HELIOCARE

HELIOCARE 360° represents advanced, evidence-based photoprotection designed to integrate into dermatological treatment plans and support patients requiring comprehensive daily protection.

To request samples, professional materials, or patient support initiatives, please contact our team below.

As Seen In

1 6

References

  1. González S, et al. PhotodermatolPhotoimmunol Photomed,1996,12(2):45-56 996 Apr;12(2):45-56.
  2. González S, et.al. Int. J. Mol. Sci. 2018. Aug1;19(8):2250.
  3. Amini S, et al. J Am Acad Dermatol. 2010 Mar;62(3):511-3.
  4. Maritza A, et al. J. Am Acad Derm, 2004. 51(6):910-8.
  5. Alonso-Lebrero JL, et.al. PhotochemPhotobiol B. 2003 Apr;70(1):31-7.
  6. Aguilera J,et al. Front Med (Lausanne). 2021 Jun 2;8:684665.
  7. Tanew A., Radakovic S., Gonzalez S., Venturini M., Calzavara-Pinton P., Oral administration of a hydrophilic extract of Polypodium leucotomos for the prevention of polymorphic light eruption. JAAD, 2010.09.773.
  8. Stump, M.; Dhinsa, H.; Powers, J.; Stone, M. Attenuation of Actinic Prurigo Eruptions with Polypodium Leucotomos Supplementation.Pediatr. Dermatol. 2022, 39, 145–146.
  9. Pacifico, A.; Damiani, G.; Iacovelli, P.; Conic, R.R.Z.; Gonzalez, S.; Morrone, A. NB-UVB plus Oral Polypodium Leucotomos Extract Display Higher Efficacy than NB-UVB Alone in Patients with Vitiligo. Dermatol. Ther. 2021, 34, e14776.
  10. Mohammad, T.F.; Kohli, I.; Nicholson, C.L.; Do, G.T.; Chaowattanapanit, S.; Nahhas, A.F.; Braunberger, T.L.; Lim, H.W.; Mda, I.H.H. Oral Polypodium Leucotomos Extract and Its Impact on Visible Light-Induced Pigmentation in Human. Subjects. J. Drugs Dermatol. 2019, 18, 1198–1203.
  11. Schalka, S.; Donato, L.C. Evaluation of Effectiveness of a Sunscreen Containing Polypodium Leucatomos Extract in Reducing the Sun Damage to the Skin. Surg. Cosmet. Dermatol. 2019, 11, 310–318.
  12. Lamberti, A.; Cartocci, A.; Donelli, C.; Cortonesi, G.; Trovato, E.; Milani, M.; Rubegni, P.; Cinotti, E. Prevention Strategies in Patients Affected by Actinic Keratosis of the Head: A 12-Month, Prospective, Assessor-Blinded, Controlled Study with Lesion-Directed Treatment Associated with Medicalized Photoprotection; Longdom Publishing SL: Barcelona, Spain, 2022; Volume 13, p. 5.